Publications
Detailed Information
Phosphorylation of ERK1/2 and Prognosis of Clear Cell Renal Cell Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyun Ju | - |
dc.contributor.author | Kim, Dong-Il | - |
dc.contributor.author | Kang, Gyeong Hoon | - |
dc.contributor.author | Kwak, Cheol | - |
dc.contributor.author | Moon, Kyung Chul | - |
dc.contributor.author | Ku, Ja Hyeon | - |
dc.date.accessioned | 2012-06-04T05:35:45Z | - |
dc.date.available | 2012-06-04T05:35:45Z | - |
dc.date.issued | 2009-02 | - |
dc.identifier.citation | UROLOGY; Vol.73 2; 394-399 | ko_KR |
dc.identifier.issn | 0090-4295 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76783 | - |
dc.description.abstract | OBJECTIVES To evaluate the phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) in clear cell renal cell carcinoma (CCRCC) and to investigate its prognostic significance. ERK1/2 activation had been reported in RCC, but little is known about its prognostic significance. METHODS We immunohistochemically analyzed phosphorylated ERK1/2 (pERK) expression using tissue microarrays in 328 CCRCC specimens. The percentage of tumor cells showing positive staining was evaluated and classified into 4 categories: 0, 0%; 1+, 1%-10%; 2+, 11%-50%; and 3+, >50%. For statistical analysis, the cases were subdivided into pERK-low (0 and 1+) and pERK-high (2+ and 3+) expression. RESULTS Our study showed significantly greater expression of pERK in CCRCC than in non-neoplastic renal parenchyma. pERK-high expression was significantly associated with a low pT category (P = .046). The survival analysis showed a significant association between pERK-high expression and better progression-free survival (P = .014). Furthermore, the prognostic significance of pERK expression was quite different between small CCRCC (size <= 7 cm) and large CCRCC (size >7 cm) lesions. In small CCRCC, pERK-high expression correlated significantly with better cancer-specific survival (P = .018) and better progression-free survival (P < .001). However, no correlation was found between pERK expression and survival in large CCRCC. CONCLUSIONS High expression of pERK in CCRCC was associated with a low pT category and showed a longer progression-free survival, especially in small CCRCC. Although the biologic mechanism of the ERK pathway in CCRCC remains unknown, the results of this study suggest that pERK expression is a positive prognosticator for survival in those with small CCRCC. UROLOGY 73: 394-399, 2009. (C) 2009 Published by Elsevier Inc. | ko_KR |
dc.description.sponsorship | This work was supported by grant 03-2005-004 from the Seoul National University
Hospital Research Fund. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCIENCE INC | ko_KR |
dc.title | Phosphorylation of ERK1/2 and Prognosis of Clear Cell Renal Cell Carcinoma | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이현주 | - |
dc.contributor.AlternativeAuthor | 김동일 | - |
dc.contributor.AlternativeAuthor | 강경훈 | - |
dc.contributor.AlternativeAuthor | 곽철 | - |
dc.contributor.AlternativeAuthor | 구자현 | - |
dc.contributor.AlternativeAuthor | 문경철 | - |
dc.identifier.doi | 10.1016/j.urology.2008.08.472 | - |
dc.citation.journaltitle | UROLOGY | - |
dc.description.citedreference | Schmitz KJ, 2007, VIRCHOWS ARCH, V450, P151, DOI 10.1007/s00428-006-0342-y | - |
dc.description.citedreference | Weiss RH, 2007, J UROLOGY, V177, P63, DOI 10.1016/j.juro.2006.08.073 | - |
dc.description.citedreference | Murphy DA, 2006, AM J PATHOL, V169, P1875, DOI 10.2353/ajpath.2006.050711 | - |
dc.description.citedreference | McLaughlin JK, 2006, SEMIN ONCOL, V33, P527, DOI 10.1053/j.seminoncol.2006.06.010 | - |
dc.description.citedreference | Shuch BM, 2006, SEMIN ONCOL, V33, P563, DOI 10.1053/j.seminoncol.2006.06.006 | - |
dc.description.citedreference | Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x | - |
dc.description.citedreference | Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002 | - |
dc.description.citedreference | Chadha KS, 2006, ANN SURG ONCOL, V13, P933, DOI 10.1245/ASO.2006.07.011 | - |
dc.description.citedreference | Lopez-Beltran A, 2006, EUR UROL, V49, P798, DOI 10.1016/j.eururo.2005.11.035 | - |
dc.description.citedreference | Milde-Langosch K, 2005, BRIT J CANCER, V92, P2206, DOI 10.1038/sj.bjc.6602655 | - |
dc.description.citedreference | Amato RJ, 2005, ANN ONCOL, V16, P7, DOI 10.1093/annonc/mdi002 | - |
dc.description.citedreference | WALTER MS, 2005, CANCER, V104, P2323 | - |
dc.description.citedreference | Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644 | - |
dc.description.citedreference | Handra-Luca A, 2003, AM J PATHOL, V163, P957 | - |
dc.description.citedreference | Blackhall FH, 2003, CLIN CANCER RES, V9, P2241 | - |
dc.description.citedreference | SOBIN LH, 2002, UICC TNM CLASSIFICAT | - |
dc.description.citedreference | Pearson G, 2001, ENDOCR REV, V22, P153 | - |
dc.description.citedreference | Kolch W, 2000, BIOCHEM J, V351, P289 | - |
dc.description.citedreference | Hoshino R, 1999, ONCOGENE, V18, P813 | - |
dc.description.citedreference | Sewing A, 1997, MOL CELL BIOL, V17, P5588 | - |
dc.description.citedreference | OKA H, 1995, CANCER RES, V55, P4182 | - |
dc.description.citedreference | FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.